Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors

Details for Australian Patent Application No. 2007202619 (hide)

Owner Amgen Inc. Medarex, Inc.

Inventors Elliot, Robin L; Boyle, William James; Medlock, Eugene; Sullivan, John Kevin

Agent Wrays

Pub. Number AU-A-2007202619

Parent 2003243139

Filing date 7 June 2007

Wipo publication date 28 June 2007

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 19/00 (2006.01) Drugs for skeletal disorders

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

28 June 2007 Application Open to Public Inspection

  Published as AU-A-2007202619

28 June 2007 Complete Application Filed

2 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007202620-Gaming machine

2007202618-Naltrexone Hydrochloride Compositions